tetano
Editor, Senior Moderator
Front Immunol. 2018 Aug 28;9:1953. doi: 10.3389/fimmu.2018.01953. eCollection 2018.
[h=1]Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections.[/h] Zacharias ZR[SUP]1[/SUP], Ross KA[SUP]2[/SUP], Hornick EE[SUP]3[/SUP], Goodman JT[SUP]2[/SUP], Narasimhan B[SUP]2[/SUP], Waldschmidt TJ[SUP]1,[/SUP][SUP]4[/SUP], Legge KL[SUP]1,[/SUP][SUP]3,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A virus (IAV) is a major cause of respiratory illness. Given the disease severity, associated economic costs, and recent appearance of novel IAV strains, there is a renewed interest in developing novel and efficacious "universal" IAV vaccination strategies. Recent studies have highlighted that immunizations capable of generating local (i.e., nasal mucosa and lung) tissue-resident memory T and B cells in addition to systemic immunity offer the greatest protection against future IAV encounters. Current IAV vaccines are designed to largely stimulate IAV-specific antibodies, but do not generate the lung-resident memory T and B cells induced during IAV infections. Herein, we report on an intranasally administered biocompatible polyanhydride nanoparticle-based IAV vaccine (IAV-nanovax) capable of providing protection against subsequent homologous and heterologous IAV infections in both inbred and outbred populations. Our findings also demonstrate that vaccination with IAV-nanovax promotes the induction of germinal center B cells within the lungs, both systemic and lung local IAV-specific antibodies, and IAV-specific lung-resident memory CD4 and CD8 T cells. Altogether our findings show that an intranasally administered nanovaccine can induce immunity within the lungs, similar to what occurs during IAV infections, and thus could prove useful as a strategy for providing "universal" protection against IAV.
[h=4]KEYWORDS:[/h] adaptive immunity; heterosubtypic protection; influenza virus; nanovaccine; tissue-resident memory
PMID: 30233573 PMCID: PMC6127617 DOI: 10.3389/fimmu.2018.01953
Free PMC Article
[h=1]Polyanhydride Nanovaccine Induces Robust Pulmonary B and T Cell Immunity and Confers Protection Against Homologous and Heterologous Influenza A Virus Infections.[/h] Zacharias ZR[SUP]1[/SUP], Ross KA[SUP]2[/SUP], Hornick EE[SUP]3[/SUP], Goodman JT[SUP]2[/SUP], Narasimhan B[SUP]2[/SUP], Waldschmidt TJ[SUP]1,[/SUP][SUP]4[/SUP], Legge KL[SUP]1,[/SUP][SUP]3,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A virus (IAV) is a major cause of respiratory illness. Given the disease severity, associated economic costs, and recent appearance of novel IAV strains, there is a renewed interest in developing novel and efficacious "universal" IAV vaccination strategies. Recent studies have highlighted that immunizations capable of generating local (i.e., nasal mucosa and lung) tissue-resident memory T and B cells in addition to systemic immunity offer the greatest protection against future IAV encounters. Current IAV vaccines are designed to largely stimulate IAV-specific antibodies, but do not generate the lung-resident memory T and B cells induced during IAV infections. Herein, we report on an intranasally administered biocompatible polyanhydride nanoparticle-based IAV vaccine (IAV-nanovax) capable of providing protection against subsequent homologous and heterologous IAV infections in both inbred and outbred populations. Our findings also demonstrate that vaccination with IAV-nanovax promotes the induction of germinal center B cells within the lungs, both systemic and lung local IAV-specific antibodies, and IAV-specific lung-resident memory CD4 and CD8 T cells. Altogether our findings show that an intranasally administered nanovaccine can induce immunity within the lungs, similar to what occurs during IAV infections, and thus could prove useful as a strategy for providing "universal" protection against IAV.
[h=4]KEYWORDS:[/h] adaptive immunity; heterosubtypic protection; influenza virus; nanovaccine; tissue-resident memory
PMID: 30233573 PMCID: PMC6127617 DOI: 10.3389/fimmu.2018.01953
Free PMC Article